GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » EPS without NRI

Kaken Pharmaceutical Co (TSE:4521) EPS without NRI : 円106.86 (TTM As of Dec. 2023)


View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co EPS without NRI?

Kaken Pharmaceutical Co's earnings per share without non-recurring items for the three months ended in Dec. 2023 was 円69.21. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was 円106.86.

During the past 12 months, Kaken Pharmaceutical Co's average earnings per share (NRI) Growth Rate was -65.30% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -28.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -16.00% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Kaken Pharmaceutical Co's EPS without NRI or its related term are showing as below:

TSE:4521' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -28.2   Med: 7.7   Max: 35.1
Current: -28.2

During the past 13 years, Kaken Pharmaceutical Co's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 35.10% per year. The lowest was -28.20% per year. And the median was 7.70% per year.

TSE:4521's 3-Year EPS without NRI Growth Rate is ranked worse than
85.92% of 838 companies
in the Drug Manufacturers industry
Industry Median: 10.5 vs TSE:4521: -28.20

Kaken Pharmaceutical Co's EPS (Diluted) for the three months ended in Dec. 2023 was 円68.84. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円78.04.

Kaken Pharmaceutical Co's EPS (Basic) for the three months ended in Dec. 2023 was 円68.92. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was 円78.59.


Kaken Pharmaceutical Co EPS without NRI Historical Data

The historical data trend for Kaken Pharmaceutical Co's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co EPS without NRI Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 446.64 501.48 339.27 317.65 185.92

Kaken Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.14 -71.77 67.71 41.71 69.21

Competitive Comparison of Kaken Pharmaceutical Co's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's PE Ratio without NRI falls into.



Kaken Pharmaceutical Co EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円106.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kaken Pharmaceutical Co  (TSE:4521) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Kaken Pharmaceutical Co EPS without NRI Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co (TSE:4521) Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines